Results 71 to 80 of about 1,763 (188)

Advances and Prospects of Stereotactic Radiosurgery and Stereotactic Ablative Body Radiotherapy: Evolving Paradigms in Precision Oncology

open access: yesMed Research, Volume 2, Issue 1, Page 157-180, March 2026.
The graphical abstract outlines the progressive development and impact of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Technological Evolution illustrates the transition from brachytherapy with single‐dose, LDR/HDR schedules to fractionated radiotherapy, three‐dimensional conformal radiotherapy (3DCRT) and Gamma Knife ...
Jing Zhang   +10 more
wiley   +1 more source

Impact of local treatment on survival outcomes in patients with metastatic lung cancer with oligoprogression undergoing immunotherapy

open access: yesSwiss Medical Weekly
PURPOSE: Immune checkpoint inhibitors have revolutionised the management of non-small cell lung cancer (NSCLC) without oncogenic addictions and have improved its prognosis. A manifestation of acquired resistance to immunotherapy, which is typically seen
Barbara Domenach   +6 more
doaj   +1 more source

Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy

open access: yes, 2021
Objectives: To report outcomes of stereotactic body radiotherapy (SBRT) in metastatic castration-resistant prostate cancer (mCRPC) patients with oligoprogression (≤ 5 metastases) during first-line treatment with androgen receptor-targeted therapy (ARTT).
Borghesi S.   +37 more
core   +1 more source

Oligoprogression [PDF]

open access: yes, 2020
Bálint Botz   +2 more
openaire   +2 more sources

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non‐Small Cell Lung Cancer With ROS1 Rearrangement

open access: yesCancer Medicine, Volume 15, Issue 2, February 2026.
Survival outcomes in gradual/local progression group were superior to dramatic progression group; survival period of dramatic progression group who received chemotherapy was longer than that of other therapies. ROS1 kinase domain mutations were detected predominantly in dramatic progression group, whereas activation of bypass and downstream pathways ...
Quan‐Quan Tan   +10 more
wiley   +1 more source

PSMA PET‐directed radiotherapy for prostate cancer: From precision planning to future innovations

open access: yesVIEW, Volume 7, Issue 1, February 2026.
Prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) imaging enables highly sensitive detection of prostate cancer recurrence and precise lesion mapping. This review summarizes current evidence and emerging applications of PSMA PET in radiotherapy, including diagnostic staging, target delineation, adaptive planning, and outcome ...
Wenpeng Huang   +7 more
wiley   +1 more source

Dataset related to article "Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection"

open access: yes, 2022
This record contains raw data related to article "Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection" Abstract: Oligoprogression is ...
Perrino M   +9 more
core   +1 more source

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer:how to treat and when? [PDF]

open access: yes, 2020
Up to 70% of non-small cell lung cancer (NSCLC) patients develop central nervous system (CNS) metastases during the course of their disease, especially those with oncogenic drivers treated with a first-generation tyrosine kinase inhibitor (TKI), because ...
Schoenmaekers, Janna Josephus Anna Oda   +13 more
core   +1 more source

Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin‐4 Loss

open access: yesIJU Case Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Introduction Enfortumab vedotin is a standard therapy for advanced urothelial carcinoma, but its efficacy may be limited by acquired resistance and spatial heterogeneity of Nectin‐4 expression. Case Presentation We report the case of a 76‐year‐old woman with cT3N2M0 left renal pelvic urothelial carcinoma that was treated with first‐line ...
Takahito Wakamiya   +6 more
wiley   +1 more source

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)

open access: yesFrontiers in Pharmacology
ObjectiveTo investigate the efficacy of anlotinib, an antiangiogenic multikinase inhibitor, as an add-on therapy to first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) for patients with EGFR-mutant non-small cell lung ...
Fei Zhou   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy